Cargando…

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?

Detalles Bibliográficos
Autores principales:	Rustin, G. J. S., Hall, M. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959931/ https://www.ncbi.nlm.nih.gov/pubmed/27358387 http://dx.doi.org/10.1093/annonc/mdw253

Ejemplares similares

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

CA-125 is not a useful marker in metastatic breast cancer.
por: Seckl, M. J., et al.
Publicado: (1992)

Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
por: Rong, Yan, et al.
Publicado: (2021)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

CA125 effects on humoral immunosuppression
por: Kline, J. Bradford, et al.
Publicado: (2017)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
por: Gupta, Digant, et al.
Publicado: (2010)

Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
por: Pelissier, Aurélie, et al.
Publicado: (2016)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

Role of tumour markers in monitoring epithelial ovarian cancer
por: Meyer, T, et al.
Publicado: (2000)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
por: Winarno, G. N. A., et al.
Publicado: (2020)

Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer Patients with Low CA125 Concentration
por: Zhang, Hongyan, et al.
Publicado: (2019)

CA 125 half-life in ovarian cancer: a multivariate survival analysis.
por: Yedema, C. A., et al.
Publicado: (1993)

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer
por: Schram, Alison M., et al.
Publicado: (2016)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
por: Menon, U, et al.
Publicado: (1999)

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.
por: Hawkins, R. E., et al.
Publicado: (1989)

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125.
por: Fisken, J., et al.
Publicado: (1993)

CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels
por: Wang, Yi-Sheng, et al.
Publicado: (2021)

Preoperative CA-125 in low-grade endometrial cancer: risk stratification and implications for treatment
por: Kwon, Janice S.
Publicado: (2019)

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
por: Anastasi, Emanuela, et al.
Publicado: (2013)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer
por: Chiang, An Jen, et al.
Publicado: (2014)

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2021)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Effect of Circulating Antigen on Immunoscintigraphy of Ovarian Cancer Patients Using Anti‐CA125 Monoclonal Antibody
por: Sakahara, Harumi, et al.
Publicado: (1996)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rf425ek72phcbdam8sv12ul598